Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
Authors:
Open Access
- 27 March 2024
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 126, 102724
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Neoadjuvant therapy in non-small cell lung cancerCritical Reviews in Oncology/Hematology, 2023
- Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-AnalysisJournal of Thoracic Oncology, 2023
- Neoadjuvant Targeted Therapy in Non–Small Cell Lung Cancer and Its Impact on Surgical OutcomesAnnals of Thoracic Surgery Short Reports, 2022
- Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050International Journal of Clinical Oncology, 2022
- Screening for Lung CancerJAMA, 2021
- FP01.05 The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLCJournal of Thoracic Oncology, 2021
- PS01.02 National Lung Cancer Screening Program in Taiwan: The TALENT StudyJournal of Thoracic Oncology, 2021
- Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non–small cell lung cancer: A phase II studyThe Journal of Thoracic and Cardiovascular Surgery, 2021
- Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future ApproachesJournal of Thoracic Oncology, 2020
- Osimertinib: First Global ApprovalDrugs, 2016